- Home
- CNSP vs BCAB Comparison
CNSP vs BCAB Comparison
Compare CNSP & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | BCAB |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNSP | BCAB |
|---|---|---|
| Price | $5.23 | $3.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 8.2K | ★ 46.8K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.03 | ★ 29.86 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $0.12 |
| 52 Week High | $10.59 | $6.52 |
Technical Indicators
Market Signals| Indicator | CNSP | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 40.56 |
| Support Level | $5.15 | $3.31 |
| Resistance Level | $5.53 | $4.24 |
| Average True Range (ATR) | 0.43 | 0.36 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 52.76 | 10.90 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.